Rivaroxaban thromboprophylaxis for gastric/gastroesophageal junction tumors versus other tumors: A post hoc analysis of the randomized CASSINI trial.

Jodi V MonesMichael B StreiffAlok A KhoranaGemma A BendheimC V DamarajuPeter WildgoosePaul BurtonHanno RiessGerald A Soff

Published in: Research and practice in thrombosis and haemostasis (2021)

Excluding patients with G/GEJ tumors resulted in a definable population of cancer patients who achieved an improved benefit-risk balance from rivaroxaban prophylaxis.

Keyphrases

venous thromboembolism
phase iii
atrial fibrillation
phase ii
pulmonary embolism
open label
clinical trial
papillary thyroid
double blind
study protocol
randomized controlled trial
young adults
lymph node metastasis